Rituximab biosimilar - International Biotech Center Generium

Drug Profile

Rituximab biosimilar - International Biotech Center Generium

Alternative Names: Deplera; GNR-006

Latest Information Update: 26 Oct 2015

Price : $50

At a glance

  • Originator International Biotech Center Generium
  • Developer International Biotechnology Center Generium
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical B cell lymphoma

Most Recent Events

  • 26 Oct 2015 Preclinical trials in B-cell lymphoma in Russia (Parenteral) before October 2015
  • 26 Oct 2015 Russian regulatory authority approves IND application for GNR 006 in B-cell lymphoma (Generium's website, October 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top